Empiric Antibiotic Therapy for IV Drug Users with Skin Infections

Initial Assessment and Classification

The Infectious Diseases Society of America recommends determining if the infection is purulent or non-purulent as this affects antibiotic choice 3
Assess for signs of systemic infection, such as fever or elevated heart rate, which necessitates broader coverage 4
Look for signs of deeper infection suggesting necrotizing fasciitis or myonecrosis requiring immediate surgical consultation 2
Evaluate for complications common in IV drug users, such as endocarditis, septic thrombophlebitis, or osteomyelitis 1

For mild purulent infections, the American College of Clinical Pharmacy recommends trimethoprim-sulfamethoxazole 160-800 mg twice daily 3
For mild non-purulent infections, the Infectious Diseases Society of America recommends clindamycin alone or trimethoprim-sulfamethoxazole plus amoxicillin 3
For moderate to severe infections, the Society for Healthcare Epidemiology of America recommends vancomycin 15-20 mg/kg IV every 8-12 hours plus piperacillin-tazobactam, a carbapenem, or ceftriaxone plus metronidazole 1, 2

The Centers for Disease Control and Prevention notes that IV drug users have a higher risk of MRSA colonization and infection, necessitating empiric MRSA coverage 1, 2
Consider polymicrobial infections including anaerobes, especially with infections near injection sites 7, 8
Higher risk of bacteremia and metastatic infections requires thorough evaluation 2

The Infectious Diseases Society of America recommends 7-14 days of therapy for complicated skin infections 3, 2
Treatment should be individualized based on clinical response 3
Longer duration may be needed if bacteremia or deeper infection is present 6

Incision and drainage is the primary treatment for abscesses, as recommended by the Surgical Infection Society 3, 4
Prompt surgical consultation for suspected necrotizing infections is recommended by the American College of Surgeons 1
Consider imaging to evaluate for deeper collections or foreign bodies 2

Reassess within 48-72 hours to evaluate response to therapy, as recommended by the Infectious Diseases Society of America 3
Consider switching to oral therapy once clinically improving 3
Screen for other complications common in IV drug users, such as endocarditis or osteomyelitis 1

Failure to consider MRSA as a causative pathogen, as noted by the Centers for Disease Control and Prevention 3, 1
Inadequate surgical drainage of abscesses, as warned by the Surgical Infection Society 3, 4
Missing deeper or necrotizing infections requiring urgent surgical intervention, as emphasized by the American College of Surgeons 1, 2